CLSPN, claspin, 63967

N. diseases: 22; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.010 Biomarker disease BEFREE CLSPN small interfering RNA treatment decreased GC cell proliferation and invasion. 30240769 2019
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.010 Biomarker disease BEFREE CLSPN small interfering RNA treatment decreased GC cell proliferation and invasion. 30240769 2019
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.010 Biomarker phenotype BEFREE CLSPN small interfering RNA treatment decreased GC cell proliferation and invasion. 30240769 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.010 Biomarker disease BEFREE Among these dysregulated RNAs, three DELs (AP002478.1, HTR2A-AS1, and ERVMER61-1) and six DEGs (enhancer of zeste homolog 2 [<i>EZH2</i>], kinesin family member 23 [<i>KIF23</i>], chromobox 2 [<i>CBX2</i>], centrosomal protein 55 [<i>CEP55</i>], cell division cycle 25A [<i>CDC25A</i>], and claspin [<i>CLSPN</i>]) were used for construct a prognostic signature for HCC overall survival (OS), and performed well in HCC OS (adjusted <i>P</i><0.0001, adjusted hazard ratio = 2.761, 95% confidence interval = 1.838-4.147). 31289599 2019
CUI: C3544205
Disease: Ovarian clear cell carcinoma
Ovarian clear cell carcinoma 		0.010 Biomarker disease BEFREE The HNF-1β-USP28-Claspin pathway upregulates DNA damage-induced Chk1 activation in ovarian clear cell carcinoma. 29707125 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.010 AlteredExpression phenotype BEFREE Functional analyses indicated that the expression TopBP1 and Claspin positively affects the survival of cancer cells and thus negatively the xenograft metastasis model animals in response to radiation. 25216549 2014
CUI: C0220650
Disease: Metastatic malignant neoplasm to brain
Metastatic malignant neoplasm to brain 		0.010 Biomarker disease BEFREE TopBP1 and Claspin contribute to the radioresistance of lung cancer brain metastases. 25216549 2014
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.010 Biomarker disease BEFREE Depletion of TopBP1 or Claspin using shRNA showed an enhancement of sensitivity to radiation in radioresistant lung cancer cells (PC14PE6). 25216549 2014
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.010 Biomarker disease BEFREE Depletion of TopBP1 or Claspin using shRNA showed an enhancement of sensitivity to radiation in radioresistant lung cancer cells (PC14PE6). 25216549 2014
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.010 Biomarker disease BEFREE Depletion of TopBP1 or Claspin using shRNA showed an enhancement of sensitivity to radiation in radioresistant lung cancer cells (PC14PE6). 25216549 2014
CUI: C0004135
Disease: Ataxia Telangiectasia
Ataxia Telangiectasia 		0.010 Biomarker disease BEFREE Both the ATR (ataxia telangiectasia and Rad3-related protein) kinase and the Replication pausing complex (RPC) components Tipin, Tim1 and Claspin play key roles in activating the intra S-phase checkpoint and in stabilizing the stalled replication forks. 22324461 2012
CUI: C0007097
Disease: Carcinoma
Carcinoma 		0.010 Biomarker group BEFREE Our results evidenced a constant and significant increase of the rate of claspin positivity from the normal tissues to carcinomas (pχ2(trend) < 0.0001). 22731782 2012
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.010 AlteredExpression phenotype BEFREE Claspin expression is significantly high in several human solid tumors. 22731782 2012
CUI: C0343641
Disease: Human papilloma virus infection
Human papilloma virus infection 		0.010 AlteredExpression disease BEFREE In order to investigate whether claspin immunoreactivity is related to the lesion severity and High-Risk (HR) HPV infection, we analyzed claspin expression by immunohistochemistry in a series of cervical biopsies which represent the steps occurring during cervical carcinogenesis (normal tissues, Cervical Intraepithelial Neoplasias 1, 2 and 3, Squamous Cell Carcinomas). 22731782 2012
CUI: C0346153
Disease: Breast Cancer, Familial
Breast Cancer, Familial 		0.010 GeneticVariation disease BEFREE To our knowledge, this is the first study reporting the mutation screening of the CLSPN gene in familial breast cancer cases. 18077083 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.020 GeneticVariation group BEFREE A separate analysis of the CLSPN c.3839C>T (rs35490896) variant that was observed more frequently in breast tumors than in pancreatic tumors or normal controls failed to detect a significant association with breast cancer risk in a Mayo Clinic breast cancer case-control study. 18281469 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.020 Biomarker group LHGDN Germline alterations in the CLSPN gene in breast cancer families. 18077083 2008
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.030 Biomarker group BEFREE Accumulating evidence suggests that Claspin inactivation could be an essential event during carcinogenesis, indicating that Claspin may function as a tumour suppressor. 28942358 2017
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.030 AlteredExpression phenotype BEFREE Accumulating evidence suggests that Claspin inactivation could be an essential event during carcinogenesis, indicating that Claspin may function as a tumour suppressor. 28942358 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.030 Biomarker group BEFREE In order to investigate whether claspin immunoreactivity is related to the lesion severity and High-Risk (HR) HPV infection, we analyzed claspin expression by immunohistochemistry in a series of cervical biopsies which represent the steps occurring during cervical carcinogenesis (normal tissues, Cervical Intraepithelial Neoplasias 1, 2 and 3, Squamous Cell Carcinomas). 22731782 2012
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.030 Biomarker phenotype BEFREE In order to investigate whether claspin immunoreactivity is related to the lesion severity and High-Risk (HR) HPV infection, we analyzed claspin expression by immunohistochemistry in a series of cervical biopsies which represent the steps occurring during cervical carcinogenesis (normal tissues, Cervical Intraepithelial Neoplasias 1, 2 and 3, Squamous Cell Carcinomas). 22731782 2012
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.030 Biomarker group BEFREE We resequenced CLSPN from the germline of selected cancer families with a history of breast cancer (n = 25) or a multicancer phenotype (n = 46) as well as from a panel of sporadic cancer cell lines (n = 52) derived from a variety of tumor types. 19737971 2009
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.030 GeneticVariation phenotype BEFREE Here, we describe a study to determine whether mutational disruption of CLSPN contributes to cancer susceptibility and sporadic tumorigenesis. 19737971 2009
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.040 AlteredExpression disease BEFREE Subsequent studies showed that BME treatment of breast cancer cells inhibited survivin and claspin expression. 20179194 2010
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.040 Biomarker disease BEFREE We resequenced CLSPN from the germline of selected cancer families with a history of breast cancer (n = 25) or a multicancer phenotype (n = 46) as well as from a panel of sporadic cancer cell lines (n = 52) derived from a variety of tumor types. 19737971 2009